Loading
Review on Mesothelin in Mesothelioma, in Clinical Cancer Research (2004), one of the most cited Europe PMC records with Mesothelin in its title.
Mesothelin is a differentiation antigen present on normal mesothelial cells and overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinoma. The mesothelin gene encodes a precursor protein that is processed to yield the 40-kDa protein, mesothelin, attached to the cell membrane by a glycosylphosphatidyl inositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor. The biological function of mesothelin is not known. Mesothelin is a promising candidate for tumor-specific therapy, given its limited expression in normal tissues and high expression in several cancers. SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin that is undergoing clinical evaluation in patients with mesothelin-expressing tumors. There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas.
Indexed on Europe PMC as PubMed record 15217923 (DOI 10.1158/1078-0432.ccr-03-0801). Its title names Mesothelin and its text names Mesothelioma; PubMed types it as a review (Research Support, Non-U.S. Gov't, Review). It was matched automatically to the idea "Treat the body cavity, not the bloodstream, for surface spread" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Regionally delivered mesothelin CAR-T with PD-1 blockade, Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Treat the body cavity, not the bloodstream, for surface spread.
Shares Regionally delivered mesothelin CAR-T with PD-1 blockade, Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Treat the body cavity, not the bloodstream, for surface spread.
Shares Regionally delivered mesothelin CAR-T with PD-1 blockade, Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Treat the body cavity, not the bloodstream, for surface spread.